BIOMARKERS TO AID CLINICAL TRIALS FOR NEURODEGENERATIVE DISEASE

Abstract

Alzheimer’s disease and Parkinson’s disease continue to affect more Australians every year, due to an ageing population and the lack of effective drugs currently available. Whilst these diseases present with different symptoms, we’ve discovered that they share a common underlying feature; the inability to clear certain metals and proteins from the brain. Our program aims to explore these clearance pathways in the brain and identify new targets to help us better diagnose and treat these diseases.

Related publications (1)

Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease

Barbara R Cardoso, Blaine R Roberts, Charles B Malpas, Lucy Vivash, Sila Genc, Michael M Saling, Patricia Desmond, Christopher Steward, Rodney J Hicks, Jason Callahan, Amy Brodtmann, Steven Collins, Stephen Macfarlane, Niall M Corcoran, Christopher M Hovens, Dennis Velakoulis, Terence J O'Brien, Dominic J Hare, Ashley I Bush

2019-01-01